Advertise on podcast: Peptides Explained

Vesugen is only three amino acids long: lysine, glutamate, and aspartate — KED. Yet it is promoted as a vascular bioregulator that may support endothelial health and even "rejuvenate" aging blood vessels. In this episode, John Garrett looks at what the endothelial research actually measured, the proposed gene-regulation mechanism, a small human blood-flow report, and the large gap between an interesting cell signal and a proven cardiovascular therapy. No hype. No dismissal. Just the biology, the evidence, and what remains unknown. INSTAGRAM CAPTION Three amino acids. K. E. D. And somehow that became a claim about "rejuvenating" aging blood vessels. Vesugen is one of the more interesting Khavinson bioregulator peptides because there is actual published endothelial-cell research behind the concept. But there is a big difference between: changing a cell marker improving endothelial function and preventing cardiovascular disease. In the new episode of Peptides Explained, I break down the mechanism, the human signal, the evidence gaps, and the question that matters most: Can Vesugen actually make aging blood vessels younger — or is the marketing way ahead of the science? Educational only. Not medical advice. #PeptidesExplained #Vesugen #KEDPeptide #Peptides #Longevity #VascularHealth #EndothelialHealth #CardiovascularHealth #HealthyAging #Biohacking #PeptideScience #MedicalScience

Introducing MIKAYLA NOGUEIRA EXCLUSIVE: The Story She’s Finally Ready to Tell from On Purpose with Jay Shetty. Follow the show: On Purpose with Jay Shetty Jay sits down with beauty creator Mikayla Nogueira to go beyond the online persona and share the real story behind her rise. Mikayla opens up about the struggles that shaped her before finding success, the viral moment that changed her life overnight, and the painful reality of a marriage impacted by addiction and divorce. She also shares how she found her way forward, reconnected with her high school first love, and launched her own beauty brand with Sephora. With Love and Gratitude, Jay Shetty Built-in protections for teens. JAY'S DAILY WISDOM DELIVERED STRAIGHT TO YOUR INBOX Join 900,000+ readers discovering how small daily shifts create big life change with my free newsletter. Subscribe here: https://news.jayshetty.me/subscribe Check out our Apple subscription to unlock bonus content of On Purpose! https://lnk.to/JayShettyPodcast What We Discuss: 00:00 Introduction 00:45 Why Share Your Story Now? 01:31 Beyond The Influencer Persona 02:46 Childhood Memories That Shaped Her 03:45 Bullying & Discovering Makeup At Age 10 05:24 The Insecurities Behind the Confidence 06:48 Expressing Her True Self Online 08:55 The Origin Of Her Passion For Makeup 11:18 Work Ethic And Thinking Big 12:37 Creating Her Very First YouTube Video 13:58 Presenting A 50-Page Business Plan 16:30 Returning To Her Hometown & Donating Makeup 18:00 Getting Hired At Ulta Beauty 23:52 Letting Go of the Future She Planned 28:10 Losing Her Job and Finding a New Path 31:34 The First Viral Video 37:08 Manifesting Success & Building A Content Engine 41:53 Experiencing Her First Cancellation 45:25 Reflecting on Past Controversies 48:56 The Mental Health Toll of Rapid Growth 52:54 The Boston Accent 56:48 Meeting Her Ex-Husband Cody 59:41 Navigating Addiction In A Relationship 01:04:08 Dating An Influencer & Dating An Addict 01:05:56 Marriage Through Addiction and Relapse 01:13:00 A Harrowing Late-Night Emergency 01:18:11 Making the Decision to Divorce 01:33:53 The Path To Divorce 01:40:46 Finally A Fresh Start 01:46:45 Reconnecting With High School First Love, Zach 01:52:21 Building Her Beauty Brand (POV) 01:57:30 Looking Back 01:59:34 Mikayla On Final Five Episode Resources: Facebook | https://www.facebook.com/share/1C43BCLCFi/?mibextid=wwXIfr TikTok | https://www.tiktok.com/@mikaylanogueira Instagram | https://www.instagram.com/mikaylajmakeup Learn more about your ad choices. Visit podcastchoices.com/adchoices DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to [email protected].

FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.

Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease. But is a vial labeled "Follistatin-344" equivalent to the therapy used in those trials? John Garrett explains FST288, FST315, and FST344; the myostatin/activin pathway; the difference between gene therapy and recombinant protein; the evidence for muscle size versus function; and the key safety and product-identity questions. Follistatin is not an FDA-approved muscle-building medication. Educational content only; not medical advice. Explore the free Peptides Explained app: https://app.peptidesexplained.info

Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them? John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels. The key question: where does established biology end and wellness marketing begin? Educational only. Not medical advice.

For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily. This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semaglutide, tirzepatide, and retatrutide. John breaks down half-life, peaks, troughs, total exposure, and why changing the schedule does not automatically mean using less drug. We also examine the major evidence gap: once-weekly dosing has a strong clinical foundation for semaglutide and tirzepatide, while retatrutide remains investigational — and direct randomized evidence showing routine split dosing is superior is not established. Educational only. No individualized dosing protocols are provided.

Download The Peptide App at ThePeptide.App/Explained For more information on research peptides check out PeptidesExplained.info/OfflinePeptides A peptide…in a pill? Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasis. In Phase 3 trials, it produced substantial skin clearance and outperformed an established oral comparator on several key endpoints. But the biggest story may be the delivery platform itself. Peptides usually struggle to survive the digestive tract and reach circulation. Icotyde shows what can happen when medicinal chemistry, structural engineering and extreme receptor potency come together. This episode breaks down what worked, what the safety data show, and what this does—and does not—mean for the future of oral peptides. Educational only. Not medical advice.

If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials? This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak. John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists. Educational only. Not medical advice.

Download The Peptide App @ ThePeptide.App/Explained For more info on research peptides visit PeptidesExplained.info/OfflinePeptides John Garrett shares his N=1 experience with the so-called "Trinity Stack"—established TRT, retatrutide, and tesamorelin—combined with resistance training, Zone 2 cardio, high protein intake, creatine, sauna, and cold plunging. The transformation was dramatic. But what likely came from appetite control? What helped preserve muscle? What might the GH/IGF-1 axis have added? And how much credit belongs to the boring fundamentals? This is a candid personal testimony and accessible science breakdown—not a deep dive, a dosing guide, or a warning lecture. John also explains what happened during an eight-week break and why he recently restarted with a goal of reaching 10% body fat. Educational only. Retatrutide remains investigational and is not FDA-approved.

SNAP-8 is a synthetic cosmetic octapeptide marketed for expression lines and frequently called "Botox in a bottle." John Garrett, RN, breaks down the SNAP-25 and SNARE-complex mechanism, the difference between topical SNAP-8 and injected botulinum toxin, the skin-penetration problem, the Argireline evidence, a small 2024 microneedle combination study, safety, and the limits of the current human data. The mechanism is plausible. The evidence is not strong enough to call it a needle-free Botox equivalent. Educational content only; not medical advice.

Visit peptidesexplained.info for more info and resources For more info on research peptides check out PeptidesExplained.info/OfflinePeptides or email John at [email protected] What exactly is GLP-1 microdosing? Depending on who you ask, it can mean remaining on the starter dose, taking a fraction of that dose, spacing injections farther apart, stepping down after weight loss, or using a tiny amount for food noise and longevity. Those are not the same strategy. John Garrett breaks down the new low-dose semaglutide and tirzepatide data, FDA-approved dose structures, weight-regain research, maintenance questions, side effects, and the major gap between individualized clinical titration and social-media "microdosing" protocols. Educational content only. Not medical advice.

Can a peptide reverse age-related immune decline? Thymalin and Thymogen are often discussed together, but one is a complex calf-thymus extract and the other is the defined dipeptide Glu-Trp. John Garrett explains thymic involution, T-cell biology, proposed mechanisms, the Russian clinical history, limitations of the human evidence, safety, and U.S. regulatory status. The science is interesting. The "immune rejuvenation" and life-extension claims remain unproven. Educational only. Not medical advice.

Check out The Peptide App here: thepeptide.app/explained What is Pinealon, and does this three-amino-acid peptide really protect the aging brain? Pinealon—also called EDR or Glu-Asp-Arg—is a synthetic tripeptide associated with the Khavinson bioregulator research program. It is discussed for memory, neuroprotection, oxidative stress, brain aging, and even Alzheimer's disease, but the evidence is much more complicated than the marketing language suggests. John Garrett, examines Pinealon's proposed mechanism, cell and animal research, a newer induced-neuron study, and the PubMed-indexed human reports that are often overlooked. The episode also explains why Pinealon is different from Epitalon, where the human evidence is weak, what remains unknown about brain exposure and long-term safety, and why a plausible mechanism is not the same thing as an established cognitive therapy. Educational content only. Not medical advice.

What are Khavinson peptide bioregulators, and what do they actually do? John Garrett examines the Russian research tradition behind organ-derived peptide complexes and synthetic ultrashort peptides. This episode explains the proposed gene-expression mechanism, the claim of tissue specificity, common examples such as Thymalin and Epitalon, the limitations of the human evidence, oral absorption questions, product-quality concerns, safety, and U.S. regulatory status. The science is more interesting than a simple dismissal—but less proven than organ-rejuvenation marketing suggests. This episode is educational and is not medical advice.

Does a weight-loss plateau mean your GLP-1 receptors have become desensitized? John separates cellular receptor biology from whole-body weight regulation and compares semaglutide, tirzepatide, and investigational retatrutide. We examine appetite suppression, food noise, gastric-emptying tachyphylaxis, metabolic adaptation, switching therapies, and what the clinical evidence can—and cannot—tell us. A plateau is real. "Receptor burnout" is a much bigger claim. Educational only; not medical advice.